RAFAEL HOLDINGS, INC. Net Income (Loss) from Discontinued Operations Available to Common Shareholders, Basic
RAFAEL HOLDINGS, INC. (RFL) reported Net Income (Loss) from Discontinued Operations Available to Common Shareholders, Basic of $6.54 million for the 9-month period ending 2023-04-30, per its 10-Q filed 2023-06-13.
Discontinued › Income Statement › Other Income
us-gaap:NetIncomeLossFromDiscontinuedOperationsAvailableToCommonShareholdersBasic · last filed 2023-06-13
- RAFAEL HOLDINGS, INC. net income (loss) from discontinued operations available to common shareholders, basic for the quarter ending 2023-04-30 was $0.00.
- RAFAEL HOLDINGS, INC. net income (loss) from discontinued operations available to common shareholders, basic for the quarter ending 2023-01-31 was -$157.00K.
- RAFAEL HOLDINGS, INC. net income (loss) from discontinued operations available to common shareholders, basic for the quarter ending 2022-10-31 was -$3.00K, a 102.05% decline year-over-year.
- RAFAEL HOLDINGS, INC. net income (loss) from discontinued operations available to common shareholders, basic for the quarter ending 2022-07-31 was $3.45M.
- RAFAEL HOLDINGS, INC. net income (loss) from discontinued operations available to common shareholders, basic for fiscal 2022 was $1.83M, a 7.33% increase from fiscal 2021.
- RAFAEL HOLDINGS, INC. net income (loss) from discontinued operations available to common shareholders, basic for fiscal 2021 was $1.71M.
| Period end | Net Income (Loss) from Discontinued Operations Available to Common Shareholders, Basic 3 month | Net Income (Loss) from Discontinued Operations Available to Common Shareholders, Basic 6 month | Net Income (Loss) from Discontinued Operations Available to Common Shareholders, Basic 9 month | Net Income (Loss) from Discontinued Operations Available to Common Shareholders, Basic 12 month |
|---|---|---|---|---|
| 2023-04-30 | $0.00 derived: 10-Q 9 month − 10-Q 6 month · filed 2023-06-13 | -$157.00K derived: sum of 2 quarters · filed 2023-06-13 | $6.54M 10-Q · filed 2023-06-13 | $3.29M derived: sum of 4 quarters · filed 2023-06-13 |
| 2023-01-31 | -$157.00K 10-Q · filed 2023-03-14 | $6.54M 10-Q · filed 2023-03-14 | $3.29M derived: sum of 3 quarters · filed 2023-03-14 | $2.72M derived: sum of 4 quarters · filed 2023-06-13 |
| 2022-10-31 | -$3.00K 10-Q · filed 2022-12-13 | $3.44M derived: sum of 2 quarters · filed 2022-12-13 | $2.88M derived: sum of 3 quarters · filed 2023-06-13 | $2.37M derived: sum of 4 quarters · filed 2023-06-13 |
| 2022-07-31 | $3.45M derived: 10-K 12 month − 10-Q 9 month · filed 2022-10-31 | $2.88M derived: sum of 2 quarters · filed 2023-06-13 | $2.37M derived: sum of 3 quarters · filed 2023-06-13 | $1.83M 10-K · filed 2022-10-31 |
| 2022-04-30 | -$565.00K 10-Q · filed 2023-06-13 | -$1.07M derived: sum of 2 quarters · filed 2023-06-13 | -$1.62M 10-Q · filed 2023-06-13 | |
| 2022-01-31 | -$508.00K 10-Q · filed 2023-03-14 | -$1.05M 10-Q · filed 2023-03-14 | ||
| 2021-10-31 | $146.00K 10-Q · filed 2022-12-13 | |||
| 2021-07-31 | $1.71M 10-K · filed 2022-10-31 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Aditxt, Inc. (ADTX) | United States | $0.000B | |
| CDT Equity Inc. (CDT) | United States | $0.000B | -0.01 |
| Protagenic Therapeutics, Inc.\new (PTIX) | United States | $0.001B | |
| Decoy Therapeutics Inc. (DCOY) | United States | $0.002B | -0.27 |
| Nexentis Technologies Inc. (NXTS) | $0.002B | ||
| ORAGENICS INC (OGEN) | United States | $0.002B | |
| JUPITER NEUROSCIENCES, INC. (JUNS) | United States | $0.002B | -0.02 |
| BioXcel Therapeutics, Inc. (BTAI) | United States | $0.002B | |
| ZyVersa Therapeutics, Inc. (ZVSA) | United States | $0.002B | |
| Matinas BioPharma Holdings, Inc. (MTNB) | United States | $0.003B |